CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Cryoport, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$16.98+0.14 (+0.83%)

Close on Oct 19, 2026

Market cap: $856.52M
P/E (TTM): –
Dividend yield: –

Dividends

Cryoport has not reported a dividend

No dividend per share appears in Cryoport's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Cryoport's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on May 19, 2015
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CYRX.

Revenue growth12.1% · median 0.5%

Gross margin47.1% · median 40.8%

Operating margin-21.2% · median -13.4%

Net margin-20.1% · median -26.3%

Company	Revenue	Growth
MRVI	$208.78M	-5.0%
KMDA	$191.85M	+13.2%
CYRX	$186.45M	+12.1%
HRTX	$151.18M	+1.0%
LFCR	$128.87M	+0.5%
LAB	$84.60M	-4.8%

Company

Next earnings (est.): Nov 3, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 738
Held by institutions: 93.9%
Auditor: Deloitte & Touche LLP
SEC CIK: 1124524

Advertisement
300 × 250